3 completed, 2 active not recruiting, 2 terminated, 1 enrolling by invitation. 10 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 10 | Completed 3, Active not recruiting 2, Terminated 2, Enrolling by invitation 1, Recruiting 1, Unknown 1 |
Follow Skin Abnormalities: new trials by email Literature Review of Skin Abnormalities trials Research Report on Skin Abnormalities
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Thera-Clean® Microbubbles System in Patients With Skin Diseases TheraClean - Epidermolysis Bullosa, Ichthyosis | Early Phase 1 | Enrolling by invitation | Northwestern University | 20 | 2026-01-13 | 2026-02-03 |
| Repurposing Dupilumab for Management of Pruritic Genetic Inflammatory Skin Disorders Dupilumab - Skin Diseases | Early Phase 1 | Recruiting | Northwestern University | 30 | 2023-06-12 | 2026-05-01 |
| Characterization of the Microbiome in Colonized Dystrophic and Junctional Epidermolysis Bullosa Wounds Before and After Use of APR-TD011 ® Spray Solution APR-TD011 - Epidermolysis Bullosa | Early Phase 1 | Completed | Northwestern University | 15 | 2023-02-06 | 2025-04-27 |
| Rigosertib in Patients With Recessive Dystrophic Epidermolysis Bullosa Associated SCC Rigosertib Sodium, Quality-of-Life Assessment - Recessive Dystrophic Epidermolysis Bullosa | Early Phase 1 | Completed | Thomas Jefferson University | 3 | 2021-08-24 | 2025-08-01 |
| An Open-Label and Long-Term Extension Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Patients With Ichthyoses Ustekinumab - Ichthyosis | Early Phase 1 | Completed | Northwestern University | 13 | 2021-04-01 | 2025-02-12 |
| Self-Assembled Skin Substitute for the Treatment of Epidermolysis Bullosa SASS - Epidermolysis Bullosa Dystrophica | Early Phase 1 | Active not recruiting | CHU de Quebec-Universite Laval | 1 | 2019-12-10 | 2026-03-19 |
| Two Point Discrimination Two-point discrimination training, One-point discrimination training - Ehlers-Danlos Syndrome (EDS), Complex Regional Pain Syndrome (CRPS) | Early Phase 1 | Active not recruiting | Children's Hospital Medical Center, Cincinnati | 60 | 2018-07-21 | 2025-01-06 |
| Safety of Formalin-free Fixatives for In-Vivo Fixation of Skin Lesions. Formulations for in-vivo fixation - Skin Abnormality | Early Phase 1 | Unknown | Hillel Yaffe Medical Center | 200 | 2010-12-01 | 2010-08-06 |
| Evaluation of Effects of HP828-101 for Moisture Associated Skin Damage HP828-101 - Skin Abnormalities | Early Phase 1 | Terminated | Healthpoint | 7 | 2010-04-01 | 2013-12-06 |
| Allogeneic Stem Cell Transplantation (ALLOSCT) in Recessive Dystrophic Epidermolysis Bullosa (RDEB) Palifermin, Fludarabine, Busulfan - Epidermolysis Bullosa | Early Phase 1 | Terminated | Columbia University | 3 | 2009-08-20 | 2021-08-17 |
Epidermolysis Bullosa (4) · Epidermolysis Bullosa Dystrophica (3) · Ichthyosis (3) · Chronic Pain (1) · Complex Regional Pain Syndromes (1) · Dermatitis, Atopic (1) · Ehlers-Danlos Syndrome (1) · Fibromyalgia (1) · Low Back Pain (1) · Pain (1) · Pruritus (1) · Psoriasis (1) · Skin Diseases (1)
Congenital Abnormalities (10) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (10) · Skin and Connective Tissue Diseases (10) · Skin Diseases (9) · Genetic Diseases, Inborn (7) · Skin Diseases, Genetic (7) · Skin Diseases, Vesiculobullous (6) · Collagen Diseases (4) · Connective Tissue Diseases (4) · Infant, Newborn, Diseases (3) · Keratosis (3) · Epidermolysis Bullosa (2) · Pathological Conditions, Signs and Symptoms (2) · Signs and Symptoms (2)
Alemtuzumab (1) · Busulfan (1) · Fibroblast Growth Factor 7 (1) · Lorazepam (1) · ON 01910 (1) · Tacrolimus (1) · Ustekinumab (1) · dupilumab (1) · fludarabine (1) · fludarabine phosphate (1)
Northwestern University (4) · CHU de Quebec-Universite Laval (1) · Children's Hospital Medical Center, Cincinnati (1) · Columbia University (1) · Healthpoint (1) · Hillel Yaffe Medical Center (1) · Thomas Jefferson University (1)
United States (8) · Canada (1) · Israel (1)
Amy Paller, MD (2) · Amy Paller (1) · Angela Christiano, PhD (1) · Herbert B Slade, MD (1) · Neda Nikbakht, MD, PhD (1) · Neeta Nayak, MD (1) · Robert C Coghill, Ph.D. (1)